Former Dutko Worldwide lobbyist Darren Willcox has signed up nine new clients this week, Senate records show, walking away with perhaps $100,000 or more in monthly income from his struggling one-time employer.

A message left Friday morning at Willcox’s office was not returned. Dutko CEO Mark Irion, however, confirmed that his former colleague had recently enticed seven big-name clients to jump ship: Abbott Laboratories, device-maker DJO Inc., Biogen Idec, Genentech Inc., Genzyme Corp., GlaxoSmithKline and Medtronic Inc.

Senate records do not indicate how much Willcox’s new firm will be paid, but the seven clients paid Dutko $680,000 during the first six months of the year.

Irion said that Dutko and Willcox’s firm, W Strategies, “continue to work together” on lobbying work for the Pharmaceutical Research and Manufacturers of America and the California Healthcare Institute as well as drugmaker Eisai Inc. and U.S.A.A.

Lobbying reports also show that Willcox, a former House GOP staffer, this week signed up Alexion Pharmaceuticals, which Dutko did not represent.

Dutko’s revenues were down 11 percent for the first six months of 2010 (from the first six months of 2009). That decline caused the firm to drop four spots to No. 10 on Roll Call’s recent top 25 list of lobbying revenues.